{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.2","upperLimit":"58.3","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"NUMBER","populationDescription":"mITT analysis set included all participants who have received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)","title":"Part 2: CRR as Per IMWG Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}